Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
← catalyst calendarNCT07209462 · readout ≤ 438 d
Sponsored by Mirum Pharmaceuticals, Inc. (industry) · MIRM — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
60estimated
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-22 | actual | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Fragile X Syndrome
Interventions
- Drug: Low dose of MRM-3379
- Drug: Middle Dose of MRM-3379
- Drug: High dose of MRM-3379
- Drug: Placebo
- Drug: Low dose of MRM-3379 Open-Label
Primary outcome
what the primary-completion date above is the date OFIncidence and severity of treatment-emergent adverse events and Withdrawal due to adverse events and withdrawal due to adverse events
measured Baseline to Week 12
Permalink · MIRM's whole pipeline · Catalyst calendar · Every registered study · What changed